根据年龄、血型和浓缩物类型确定的FVIII和FIX终末半衰期:来自WAPPS数据库的数据
该横断面研究从WAPPS数据库提取8022次输注数据,覆盖4832例重型血友病患者(含2222例儿童),旨在建立FVIII/FIX浓缩物终末半衰期参考值。结果显示FVIII-EHL中位15.1小时长于SHL的11.1小时,FIX-EHL中位106.9小时长于SHL的36.5小时;终末半衰期受年龄、血型、浓缩物类型和抑制剂史影响。
要点
- FVIII-EHL中位终末半衰期为15.1小时,长于FVIII-SHL的11.1小时。
- FIX-EHL中位终末半衰期为106.9小时,长于FIX-SHL的36.5小时。
- 有抑制剂史者FVIII终末半衰期减少1.3小时,FIX减少22小时。
核心结论
- 在大型血友病数据库中建立了按患者特征和浓缩物类型划分的FVIII/IX终末半衰期参考值,可指导临床实践、采购经济性评估及新疗法价值归因。
研究设计与样本
- 横断面研究,数据提取自Web-Accessible Population Pharmacokinetics Service数据库,共8022次输注数据来自4832例重型血友病患者(含2222例儿童;年龄1月龄至85岁;89%为血友病A;34%使用EHL浓缩物;9.8%有抑制剂史)。
- 组间比较采用非参数检验,终末半衰期根据患者特征和浓缩物类型建模。
主要发现
- FVIII-EHL中位终末半衰期为15.1小时,FVIII-SHL为11.1小时。
- FIX-EHL中位终末半衰期为106.9小时,FIX-SHL为36.5小时。
- FVIII终末半衰期取决于年龄、浓缩物类型、血型和抑制剂史;FIX终末半衰期随年龄增长至30岁,此后保持稳定。
- O型血者FVIII终末半衰期较短。
- 有抑制剂史者FVIII终末半衰期减少1.3小时,FIX减少22小时。
临床怎么用
- 参考值可用于临床实践,例如评估免疫耐受治疗是否成功。
- 参考值可用于采购流程的经济影响评估以及新疗法(如模拟物、基因治疗)的价值归因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-life data on pharmacokinetics of factor (F) VIII/IX concentrates, especially extended half-life (EHL), concentrates in large cohorts of persons with hemophilia are currently lacking. OBJECTIVES: This cross-sectional study aimed to establish reference values for terminal half-life (THL) for FVIII/IX concentrates according to concentrate type, age, blood group and inhibitor history. PATIENTS/METHODS: Data were extracted from the Web-Accessible Population Pharmacokinetics Service database. Groups were compared by nonparametric tests. THL was modelled according to patient characteristics and concentrate type. RESULTS: Infusion data (n = 8022) were collected from 4832 subjects (including 2222 children) with severe hemophilia (age: 1 month-85 years; 89% hemophilia A; 34% using EHL concentrates, 9.8% with history of inhibitors). THL of FVIII-EHL was longer than of FVIII standard half-life (SHL; median 15.1 vs. 11.1 h). FVIII-THL was dependent on age, concentrate type, blood group, and inhibitor history. THL of FIX-EHL was longer than of FIX-SHL (median 106.9 vs. 36.5 h). FIX-THL increased with age until 30 years and remained stable thereafter. FVIII-THL was shorter in subjects with blood group O. THL was decreased by 1.3 h for FVIII and 22 h for FIX in subjects with a positive inhibitor history. CONCLUSIONS: We established reference values for FVIII/IX concentrates according to patient characteristics and concentrate type in a large database of hemophilia patients. These reference values may inform clinical practice (e.g., assessment of immune tolerance success), economic implications of procurement processes and value attribution of novel treatments (e.g., mimetics, gene therapy).
引用
- Versloot O, Iserman E, Chelle P, et al. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. J Thromb Haemost. 2021. PMID: 34013558. doi:10.1111/jth.15395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。